SBIR/STTR Research Award

Infection Resistant Prostethic Valve Sewing Cuffs

Award identifier 4f5828d0ca19cda9d846a1e761e025b6b33e836adf849a756d7b3287368940feAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$99,994

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BIOMOD SURFACES
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (Verbatim from the Applicant's Abstract): Cardiac valve replacement using prosthetic valves is indicated when progression of degenerative disease or bacterial infection of the native valve results in valvular dysfunction, thereby impacting on cardiac output. Bacterial infection is a major complication associated with implantation of these prosthetic valves. Infections are localized to the prosthesis/tissue interface at the sewing cuff leading to cuff and annular abscess formation. The goal of this phase I project is to develop an infection-resistant knitted Dacron cuff material in vitro with optimum antimicrobial properties via thermofixation (pad/heat) dyeing of the antibiotic ciprofloxacin (Cipro). Our hypothesis is application of quinolone antibiotics to Dacron biomaterials via dyeing technology can be optimized, resulting in slow, sustained antibiotic release without the use of exogenous binders. The specific aims of this proposal are to: optimize Cipro dyeing conditions to knitted Dacron, characterize the physical properties of Cipro-dyed Dacron, determine antibiotic release over time via spectrophotometry, examine in vitro antimicrobial properties and assess antibiotic release pharmacokinetics under simulated arterial flow conditions. Phase II of this project will evaluate this novel technology in an in vivo prosthetic valve model. This technology, if successful, will be become the standard of care in the treatment of all forms of prosthetic endocarditis. PROPOSED COMMERCIAL APPLICATION: Current projections indicate that a greater number of cardiac prosthetic mechanical valves will be implanted over the next ten years, with estimates in excess of 50,000 valves per year. This technology, if applied to only mechanical heart valves, could have an annual market in excess of $25-75 million. This technology can also be applied to vascular grafts, carotid patch material, wound dressings and suture material. Additionally, this technology may have commercial application in areas such as veterinary medicine, apparel or domestic items.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.